AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, R. A.
Right arrow Articles by North, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, R. A.
Right arrow Articles by North, T. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2077-2080, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (-)-beta -2',3'-Dideoxy-3'-Thiacytidine

Robert A. Smith,1 George J. Klarmann,1 Kirsten M. Stray,1 Uta K. von Schwedler,1 Raymond F. Schinazi,2,3 Bradley D. Preston,1,* and Thomas W. North4

Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah 841121; Georgia VA Research Center for AIDS and HIV Infections2 and Department of Pediatrics, Emory University School of Medicine,3 Decatur, Georgia 30033; and Center for Comparative Medicine, University of California, Davis, California 956164

Received 18 November 1998/Returned for modification 8 March 1999/Accepted 13 May 1999

A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-beta -2',3'-dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

* Corresponding author. Mailing address: Eccles Institute of Human Genetics, University of Utah, Salt Lake City, UT 84112. Phone: (801) 585-6342. Fax: (801) 585-3501. E-mail: bpreston{at}hci.utah.edu.

Antimicrobial Agents and Chemotherapy, August 1999, p. 2077-2080, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.